Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of Cardiology and President of the Arrhythmias and Electrophysiology Committee of the Argentine Federation of Cardiology, shared a post on LinkedIn about a recent article by Tybjærg Nordestgaard et al, published in JAMA Cardiology:
”Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). Ask Tybjærg Nordestgaard et al.
Lipoprotein(a) (LP(a) levels are known to be genetically determined, and elevated levels are (for now) an independent and unmodifiable risk factor for cardiovascular disease (CVD).
A 30-year prospective follow-up study was conducted in healthy women, primarily of European descent, comparing baseline LP(a) levels, clinical thresholds, LP(a) percentiles, and a specific genotype to establish the probability of developing CVD.
Figure 1. Restricted Cubic Spline Curves of 30-Year Hazard Ratios (HRs) for Major Cardiovascular Events (A), Coronary Heart Disease (B), Ischemic Stroke (C), and Cardiovascular Death (D)
- On the X-axis (baseline levels), analyze LP(a) levels; on the Y-axis, analyze HR (>1 => Risk). On the Y-axis, Graph A: HR for MACE, B: CHD, C: Stroke and D: Death.
- Color zone: Lp(a) levels, green: LP(a) < 10, blue < 30, etc.
- Vertical dotted lines indicating different percentiles.
- The gray band represents the HR width; the narrower the band, the greater the accuracy of the data.
- ight vertical line: Density percentage: referring to the LP (a) with respect to the total population under study.
Interpretation of the graph:
- In CVD the strongest associated risk is obtained with LP ( a) > 150mg/dl ( red) ( HR=2.5)
- In MACE the risk associated with LP ( a) > 100 mg/dl ( HR: 1.8)
- It carries moderate risks in stroke and cardiac death.
- Only women with Lp(a) levels > 30 mg/dl or above the 75th percentile were associated with major cardiovascular disease.”
Title: Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a)
Authors: Tybjærg Nordestgaard, Daniel I. Chasman, Vinayaga Moorthy, Jordan M. Kraaijenhof, Nancy R. Cook, I-Min Lee, Julie E. Buring, Paul M. Ridker
Read the Full Article on JAMA Cardiology․

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 14:42Bruno Pougault: The Global Momentum Behind Innovation in Thrombosis and Hemostasis
-
Jul 13, 2026, 14:34Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026
-
Jul 13, 2026, 13:57Heghine Khachatryan: The Diagnostic Dilemma of Non-Criteria Obstetric APS
-
Jul 13, 2026, 13:49Mitra Najafi: Translating Years of Innovation into Global Scientific Dialogue at ISTH 2026
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026